tirzepatide cardiovascular risk study
Why Semaglutide's Heart Scare Failed Patients
Semaglutide’s heart scare failed patients because the feared cardiovascular risk was not borne out by the latest safety data. New December 2025 real-world analyses show no increase in heart attacks or strokes among users, overturning a two-year caution that kept many from effective therapy. Medical Disclaimer: This article is